LOGIN  |  REGISTER
Viking Therapeutics

LifeWallet to Report Fourth Quarter and Full Year 2022 Results on Friday, March 31, 2023

March 20, 2023 | Last Trade: US$0.35 0.0074 -2.06

CORAL GABLES, Fla., March 20, 2023 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) (“LifeWallet”, or “LIFW” or “the Company”), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, today announced that the Company will release its fourth quarter and full year 2022 financial results after the market closes on Friday, March 31, 2023.

LifeWallet will host a conference call and live webcast to review the Company’s fourth quarter and full year results for investors and analysts at 4:30 p.m. Eastern Time on Friday, March 31, 2023. To access this call, we encourage you to pre-register using this link: LifeWallet Q4 2022 Earnings Pre Registration.

A live webcast of the conference call will be accessible from the Investors section of LifeWallet’s website at https://www.lifewallet.com.

A replay of the webcast will be archived and accessible at investor.lifewallet.com.

About LifeWallet

Founded in 2014 as MSP Recovery, LifeWallet has become a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery leader, disrupting the antiquated healthcare reimbursement system with data-driven solutions to secure recoveries from responsible parties. LifeWallet provides comprehensive solutions for multiple industries including healthcare, legal, education, and sports NIL, while innovating technologies to help save lives. For more information, visit: lifewallet.com.

For Investors:
ICR, Inc.
Marc Griffin
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Media:
ICR, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page